Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kalaris Therapeutics ( (KLRS) ) has issued an announcement.
On December 17, 2025, Kalaris Therapeutics announced it had entered into a securities purchase agreement with a group of institutional accredited and qualified institutional investors for an oversubscribed private placement of common stock and pre-funded warrants expected to raise approximately $50 million in gross proceeds, with closing anticipated around December 19, 2025. The deal, priced at a premium to the recent Nasdaq trading average, involves the sale of 4.2 million common shares at $10.00 each and pre-funded warrants for 800,000 additional shares at $9.9999 each, with the warrants immediately exercisable but subject to ownership caps, and includes registration rights obligating Kalaris to later register the resale of the issued securities. Supported by both new and existing specialist healthcare investors and led by Morgan Stanley, Leerink Partners and William Blair, the financing extends Kalaris’s cash runway into the third quarter of 2027 and is intended to fund continued clinical development of TH103 for neovascular AMD as well as general corporate purposes, strengthening the company’s balance sheet and financial flexibility as it advances its retinal disease pipeline.
The most recent analyst rating on (KLRS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.
Spark’s Take on KLRS Stock
According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.
AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.
To see Spark’s full report on KLRS stock, click here.
More about Kalaris Therapeutics
Kalaris Therapeutics, Inc., based in Berkeley Heights, N.J., is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for prevalent, sight-threatening retinal diseases, including neovascular age-related macular degeneration (AMD). Founded by anti-VEGF pioneer Dr. Napoleone Ferrara, the company is advancing its lead candidate TH103 to address major unmet medical needs in retinal care.
Average Trading Volume: 175,149
Technical Sentiment Signal: Hold
Current Market Cap: $144.9M
See more data about KLRS stock on TipRanks’ Stock Analysis page.